Avalo Therapeutics (AVTX) vs Prothena (PRTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Prothena (PRTA) has outperformed Avalo Therapeutics (AVTX) over the past year, losing 21.6% versus a loss of 62.1%. Over five years, PRTA leads with a -83.3% price change compared with -99.9% for AVTX. Prothena is the larger company by market cap ($422.1 million vs $390.9 million), about 1.1 times the size, while Avalo Therapeutics is growing revenue faster (-86.6% vs -92.8%).
Prothena converts more of its revenue into profit, with a net margin of -2520.6% versus -132642.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVTX | PRTA |
|---|---|---|
| Share price | $6.76 | $8.22 |
| Market cap | $390.88M | $422.10M |
| 1-day change | +0.15% | -2.14% |
| YTD return | -62.78% | -13.93% |
| 1-year return | -62.09% | -21.56% |
| 5-year return | -99.89% | -83.28% |
| EPS (TTM) | $-2.26 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $59.00K | $9.68M |
| Revenue growth (YoY) | -86.62% | -92.83% |
| Net income (latest FY) | $-78.26M | $-244.09M |
| Operating margin | -123601.69% | -2216.44% |
| Net margin | -132642.37% | -2520.57% |
| 52-week high | $24.27 | $11.80 |
| 52-week low | $6.53 | $7.70 |
| Distance from 52-week high | -72.15% | -30.34% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +414.79% | +160.34% |
| Average volume | 1.80M | 487.91K |
| Shares outstanding | 57.82M | 51.35M |
| Employees | 33 | 67 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRTA has outperformed AVTX by 40.5 percentage points over the past year.
- Prothena is more profitable, keeping -2520.6 cents of every revenue dollar as net income versus -132642.4 cents for Avalo Therapeutics.
- Avalo Therapeutics grew revenue faster in its latest fiscal year (-86.62% vs -92.83%).
About Avalo Therapeutics
AVTX stock →Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
About Prothena
PRTA stock →Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies.
Health Care · Biotechnology: Pharmaceutical Preparations · 67 employees
AVTX vs PRTA FAQ
Which is bigger, Avalo Therapeutics or Prothena?
Prothena (PRTA) is larger, with a market capitalization of $422.10M compared with $390.88M for Avalo Therapeutics (AVTX).
Which stock has performed better over the past year, AVTX or PRTA?
PRTA returned -21.56% over the past 12 months, compared with -62.09% for AVTX (price return, excluding dividends). Past performance does not predict future results.
Are Avalo Therapeutics and Prothena in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.